Terms: = Leukemia AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
16 results:
1. SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia.
Marrero RJ; Cao X; Wu H; Elsayed AH; Klco JM; Ribeiro RC; Rubnitz JE; Ma X; Meshinchi S; Aplenc R; Kolb EA; Ries RE; Alonzo TA; Pounds SB; Lamba JK
Blood Adv; 2023 Jun; 7(11):2538-2550. PubMed ID: 36689724
[TBL] [Abstract] [Full Text] [Related]
2. Lymphoproliferative disease detected by breast cancer screening.
Luttwak E; Segman Y; Saban M; Gutwein O; Avivi I; Perry C; Filiavich A; Sarid N
J Med Screen; 2022 Dec; 29(4):255-259. PubMed ID: 35818749
[TBL] [Abstract] [Full Text] [Related]
3. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Dulucq S; Etienne G; Morisset S; Klein E; Chollet C; Robbesyn F; Turcq B; Tigaud I; Hayette S; Nicolini FE; Mahon FX
Ann Hematol; 2019 May; 98(5):1159-1168. PubMed ID: 30798348
[TBL] [Abstract] [Full Text] [Related]
4. Endogenous Fusarium Endophthalmitis During Treatment for Acute Myeloid leukemia, Successfully Treated with 25-Gauge Vitrectomy and Antifungal Medications.
Yoshida M; Kiyota N; Maruyama K; Kunikata H; Toyokawa M; Hagiwara S; Makimura K; Sato N; Taniuchi S; Nakazawa T
Mycopathologia; 2018 Apr; 183(2):451-457. PubMed ID: 29249044
[TBL] [Abstract] [Full Text] [Related]
5. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract] [Full Text] [Related]
6. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.
Cooley S; Weisdorf DJ; Guethlein LA; Klein JP; Wang T; Marsh SG; Spellman S; Haagenson MD; Saeturn K; Ladner M; Trachtenberg E; Parham P; Miller JS
J Immunol; 2014 May; 192(10):4592-600. PubMed ID: 24748496
[TBL] [Abstract] [Full Text] [Related]
7. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
Kutny MA; Moser BK; Laumann K; Feusner JH; Gamis A; Gregory J; Larson RA; Powell BL; Stock W; Willman CL; Woods WG; Meshinchi S
Pediatr Blood Cancer; 2012 Oct; 59(4):662-7. PubMed ID: 22378655
[TBL] [Abstract] [Full Text] [Related]
8. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Cortes JE; Kantarjian HM; Goldberg SL; Powell BL; Giles FJ; Wetzler M; Akard L; Burke JM; Kerr R; Saleh M; Salvado A; McDougall K; Albitar M; Radich J;
J Clin Oncol; 2009 Oct; 27(28):4754-9. PubMed ID: 19720924
[TBL] [Abstract] [Full Text] [Related]
9. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Lucas CM; Harris RJ; Giannoudis A; Davies A; Knight K; Watmough SJ; Wang L; Clark RE
Haematologica; 2009 Oct; 94(10):1362-7. PubMed ID: 19713230
[TBL] [Abstract] [Full Text] [Related]
10. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and leukemia Group B and Southwest Oncology Group.
Heinrich MC; Owzar K; Corless CL; Hollis D; Borden EC; Fletcher CD; Ryan CW; von Mehren M; Blanke CD; Rankin C; Benjamin RS; Bramwell VH; Demetri GD; Bertagnolli MM; Fletcher JA
J Clin Oncol; 2008 Nov; 26(33):5360-7. PubMed ID: 18955451
[TBL] [Abstract] [Full Text] [Related]
11. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.
Meshinchi S; Woods WG; Stirewalt DL; Sweetser DA; Buckley JD; Tjoa TK; Bernstein ID; Radich JP
Blood; 2001 Jan; 97(1):89-94. PubMed ID: 11133746
[TBL] [Abstract] [Full Text] [Related]
12. clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Martinelli G; Montefusco V; Testoni N; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazi F; Rosti G; Bandini G; Tura S
Haematologica; 2000 Jun; 85(6):653-8. PubMed ID: 10870124
[TBL] [Abstract] [Full Text] [Related]
13. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.
Mrózek K; Heinonen K; Lawrence D; Carroll AJ; Koduru PR; Rao KW; Strout MP; Hutchison RE; Moore JO; Mayer RJ; Schiffer CA; Bloomfield CD
Blood; 1997 Dec; 90(11):4532-8. PubMed ID: 9373264
[TBL] [Abstract] [Full Text] [Related]
14. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly.
Ferrara F; Mirto S
Br J Haematol; 1996 Mar; 92(3):627-31. PubMed ID: 8616027
[TBL] [Abstract] [Full Text] [Related]
15. A practical approach to the pathology of lymphoid neoplasms: a revised European-American classification from the International Lymphoma Study Group.
Harris NL
Important Adv Oncol; 1995; ():111-40. PubMed ID: 7672801
[TBL] [Abstract] [Full Text] [Related]
16. An overview of ocular adnexal lymphoid tumors.
Jakobiec FA; Knowles DM
Trans Am Ophthalmol Soc; 1989; 87():420-42; discussion 442-4. PubMed ID: 2562543
[TBL] [Abstract] [Full Text] [Related]
